A NEW
IMNOVID^®

(pomalidomide)

TRIPLET

IMNOVID with
bortezomib and
dexamethasone,
PVd

NOW
APPROVED
IN THE EU

for RRMM
as early as
first relapse,
post-REVLIMID^®
(lenalidomide)¹

Indication
IMNOVID in combination with bortezomib
and dexamethasone is indicated in the
treatment of adult patients with multiple
myeloma who have received at least one
prior treatment regimen including
lenalidomide.

RRMM=relapsed/refractory
multiple myeloma.

LEARN MORE

References: 1. IMNOVID [Summary
of Product Characteristics]. Utrecht,
Netherlands, Celgene Europe B.V.;
2019. 2. Dimopoulos M, et al. ASH
2018. Abstract no. 3278.

03/19 INT-POMA190004

PVd=IMNOVID+bortezomib+
dexamethasone.

PVd is the
first and only
triplet specifically
proven in a 100%
REVLIMID-exposed
RRMM population
as early as
first relapse.²